Newgenivf Group, an IVF service provider, disclosed in its Nasdaq filing that it bought 146,432 XRP tokens during 2025 and sold them all before year-end, earning $10,849 from the transactions. The company also traded Bitcoin, Ethereum, and Solana, with only Solana holdings remaining at year-end, showing a significant unrealized loss. This crypto activity is separate from its core IVF business and reflects a capital allocation strategy rather than operational revenue. Despite some realized gains, the firm reported a net loss due to Solana's price drop, highlighting the risks of corporate crypto investments.
Ripple announced an expansion of its institutional digital-asset services in Brazil, including cross-border payments, custody, stablecoins, and treasury management, serving clients like Banco Genial and Nomad. The company also plans to apply for a Vi...
Ripple reported that its RLUSD stablecoin circulation reached approximately $2.4 billion as of September 3, 2026, based on issuer disclosures and independent analytics. This figure represents the total tokens outstanding but does not indicate when th...
Ripple's head of product, Jazzi Cooper, emphasized XRP's potential as collateral in institutional credit, calling it a 'killer use case.' This is supported by new XRP Ledger amendments XLS-65 and XLS-66, which enable on-chain lending and pooled asset...
Teucrium has postponed the launch of its short XRP ETF, designed to profit when XRP's price falls, 19 times since April 2025. The latest filing sets the earliest possible start date to October 11, 2026, but this is only a permission date, not a guara...
XRP is at a critical price point near its 100-day Exponential Moving Average (EMA), which has historically acted as a strong support level leading to rallies. Analysts expect XRP to either hold above the $1.38-$1.40 zone or possibly dip to $0.95-$1 b...
